| To explore the changes of platelet function in patients with Essential Thrombocytosis(ET),to provide a theoretical basis for the decision of anticoagulation therapy and reduce the occurrence of vascular events.150 ET patients who visited our hospital from January 2017 to June2022 were selected as the observation group,and 40 healthy patients were selected as the control group.The differences in blood counts(PLT,WBC,Hb),platelet-related indexes(Mpv,PDW),platelet aggregation function(MAR),and platelet membrane surface glycoproteins(CD42b,CD41,CD61)were analyzed and compared between the two groups.According to the platelet count,ET patients were divided into high platelet count group(PLT>1000×10~9/L)and low platelet count group(PLT≤1000×10~9/L),the differences in platelet function between the two groups were analyzed.According to the different driver genes,ET patients were divided into JAK2 group,CALR group,MPL group and triple-negative group,and subgroup analysis was carried out to explore the differences in platelet function of ET patients in each group.Research found:1.There were 150 ET patients,including 70 males and 80 females,with a median age of 62.39 years.There were 78 cases of JAK2 mutation,26 cases of CALR mutation,1 case of MPL mutation,1case of JAK2 and CALR double mutation,and 44 cases of triple negative.2.Blood counts in ET group:PLT 916.37±333.48×10~9/L,WBC12.55±6.09×10~9/L,Hb 138.11±25.19g/L;Blood counts in the control group:PLT 225.90±45.82×10~9/L,WBC 5.55±1.01×10~9/L,Hb 140.60±18.42g/L,the difference between PLT and WBC was significant(P<0.01),and the difference in Hb was not significant(P=0.671).3.Platelet correlation index of ET group:Mpv 9.55±0.72f L,PDW10.58±1.41%;The control group MPV10.12±0.77f L and PDW 11.42±1.61%,the difference between MPV and PDW between the two groups was significant(P<0.05).4.ET group aggregation function MAR 80.56±11.75%;The aggregation function of the control group was MAR41.67±28.39%,and the difference was significant(P<0.01).5.Platelet membrane glycoprotein CD42b 40.00±11.45,CD4193.04±4.67,CD61 95.33±3.23 in the ET group,and platelet membrane glycoprotein in the control group:CD42b 88.76±7.06,CD41 80.77±6.60,CD61 76.37±7.16,all of which were significant(P<0.01).6.According to platelet count:High platelet count group:MAR75.21±11.19%,CD42b 41.24±10.78,CD41 93.92±4.95,CD61 95.81±3.19;Low platelet count group:MAR 82.98±11.23%,CD42b 39.44±11.75,CD41 92.64±4.49,CD61 95.12±3.24.The MAR comparison was significant(P<0.01).7.According to the driver gene group:(1)JAK2 group:MAR 80.18±11.95%,CD42b 40.95±11.76,CD41 93.59±4.73,CD61 95.14±3.34;(2)CALR group:MAR 81.72±11.07%,CD42b 37.39±11.13,CD4193.88±3.56,CD61 96.01±3.34;Triple negative group:MAR 80.55±11.97%,CD42b 39.86±11.07,CD41 91.56±4.86,CD61 95.28±2.98.(3)Triple negative group:MAR 80.55±11.97%,CD42b 39.86±11.07,CD41 91.56±4.86,CD61 95.28±2.98.There was no salience in platelet function between the three groups(P>0.05).There was one MPL mutation and one double mutation,and no statistical analysis was performed.This can be derived from the above results1.ET patients had elevated platelet counts to varying degrees,increased aggregation function,and abnormal expression of platelet membrane glycoproteins CD41,CD61 and CD42b,indicating that patients with ET had abnormal platelet function and were prone to vascular events;2.The group with a low platelet count(PLT≤1000)had a higher maximum platelet aggregation rate(MAR)than a high platelet count(PLT>1000),suggesting that the risk of thrombosis was related to platelet count;3.Different driver genes had no significant effect on platelet function. |
PDF Full Text Request